GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (STU:5Y6) » Definitions » 3-Year EPS without NRI Growth Rate

Compass Pathways (STU:5Y6) 3-Year EPS without NRI Growth Rate : 6.50% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Compass Pathways 3-Year EPS without NRI Growth Rate?

Compass Pathways's EPS without NRI for the three months ended in Jun. 2024 was €-0.52.

During the past 3 years, the average EPS without NRI Growth Rate was 6.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Compass Pathways was 6.50% per year. The lowest was -34.20% per year. And the median was -33.70% per year.


Competitive Comparison of Compass Pathways's 3-Year EPS without NRI Growth Rate

For the Medical Care Facilities subindustry, Compass Pathways's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways's 3-Year EPS without NRI Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Compass Pathways's 3-Year EPS without NRI Growth Rate falls into.



Compass Pathways 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Compass Pathways  (STU:5Y6) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Compass Pathways 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Compass Pathways's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways Headlines

No Headlines